The current client is a developer of new small molecule treatments for a wide range of respiratory diseases including asthma and COPD. The company has chosen to run dissolution tests on a new substance using ISAB's leading in vitro lung simulation tool DissolvIt[®].

DissolvIt[®] has been increasingly recognized in the inhalation industry as a leading solution for generating "IVIVC" data - that is in vitro dissolution and absorption data early on in the drug development process that closely predicts later-stage in vivo data. Such data can significantly reduce risk and costs early on in drug development.

With a growing body of publications like "In Vitro to ex Vivo/In Vivo Correlation (IVIVC) of dissolution kinetics from inhaled particulate solutes using air/blood barrier models" (Journal of Aerosol Science 2021) there is increasing interest in DissolvIt's advanced capabilities.

ISAB CEO Manoush Masarrat: "We are very pleased to be working with this new US client. This clearly demonstrates the client's confidence in our world-class expertise, and the leading in vitro capabilities of DissolvIt[®]. We are delighted to carry out this research and look forward to this exciting collaboration."

Explore DissolvIt's extensive in vitro capabilities here. (https://www.inhalation.se/inhalation-research-services/dissolvit-in-vitro-dissolution/)

Read ISAB's publications on DissolvIt[®] here. (https://www.inhalation.se/publications/)